Hypochondroplasia (HCH) is an autosomal dominant skeletal dysplasia caused by pathogenic variants in the FGFR3 gene (fibroblast growth factor receptor 3) located on chromosome 4p16.3.
Molecular confirmation is achieved through identification of a heterozygous pathogenic variant in FGFR3, supporting diagnostic clarification and differentiation from other skeletal dysplasias.
Genetic testing should be considered in individuals presenting with:
Testing is also appropriate in prenatal settings where skeletal dysplasia is suspected, in individuals with mild or atypical phenotypes, and where clinical and radiographic findings are inconclusive.
Diagnosis is based on combined clinical, radiological, and molecular assessment.
Hypochondroplasia results from gain‑of‑function variants in FGFR3, leading to impaired endochondral ossification and altered skeletal growth.
The most common variant is c.1620C>A (p.Asn540Lys; N540K), accounting for approximately 60% of molecularly confirmed cases.
The disorder demonstrates genetic heterogeneity, and not all individuals with clinical HCH have a detectable variant using standard testing approaches.
Targeted testing for recurrent FGFR3 variants, particularly N540K, may be used in cases with strong clinical suspicion. This approach provides rapid results but has limited sensitivity for rare or novel variants.
Where targeted testing is negative or inconclusive, full sequencing of FGFR3 is recommended. This is typically performed using next‑generation sequencing and may include deletion/duplication analysis. It improves detection of rare or novel variants and is important given the recognised genetic heterogeneity in HCH.
Multigene skeletal dysplasia panels may be used where diagnosis is uncertain. These panels include FGFR3 along with other genes associated with skeletal dysplasias and can assist in differentiating overlapping phenotypes.
Prenatal testing may be offered when a familial pathogenic variant is known or when ultrasound findings suggest skeletal dysplasia. Testing is performed using chorionic villus sampling or amniocentesis, allowing direct molecular analysis of fetal DNA.
Once a pathogenic variant is identified, cascade testing can be offered to relatives to determine inheritance pattern. Given autosomal dominant inheritance, there is a 50% recurrence risk for offspring of affected individuals.
mRNA testing is not part of routine diagnostic evaluation in hypochondroplasia. Most pathogenic variants in FGFR3 associated with HCH are missense variants that alter protein function rather than affecting RNA expression or splicing. As a result, DNA-based sequencing remains the primary diagnostic modality.
RNA-based analysis may be considered in specific contexts, including assessment of variants of uncertain significance where splicing effects are suspected, or in research settings evaluating transcript behaviour and downstream signalling effects.
Limitations of RNA-based approaches include the requirement for high-quality RNA samples, tissue-specific expression of FGFR3, and lack of standardisation in clinical diagnostics. At present, RNA analysis remains a specialised or research-level tool rather than a routine clinical test.
thogenic or likely pathogenic variants confirm the molecular diagnosis and support clinical management and genetic counselling.
Variants of uncertain significance require correlation with phenotype and imaging and may require further familial or functional studies.
A negative result does not exclude hypochondroplasia and may reflect undetected variants, technical limitations, or an alternative diagnosis.
Approximately 70% of individuals with clinically diagnosed hypochondroplasia have identifiable FGFR3 variants.
Rare or novel variants may not be detected or fully characterised, and interpretation challenges persist, particularly for variants of uncertain significance. Clinical assessment remains central to diagnosis.
HCH is most frequently associated with the FGFR3 p.Asn540Lys (N540K) variant, but it is increasingly recognised as a genetically heterogeneous disorder. Multiple pathogenic FGFR3 variants have been identified across different regions of the receptor, demonstrating that HCH is not caused by a single mutation.
A 2006 French study In a cohort of 25 individuals with a clinical diagnosis of HCH who tested negative for the common FGFR3 mutations, researchers identified six previously unreported FGFR3 variants associated with hypochondroplasia. A molecular diagnosis was achieved in 6 of the 25 patients (24%), while 19 patients (76%) had no identifiable FGFR3 variant at the time of testing, suggesting further genetic heterogeneity and the possibility of additional causative mechanisms.
Several of the newly identified variants affected the extracellular domain of FGFR3, with four introducing additional cysteine residues. These variants were associated with more severe skeletal phenotypes, supporting the concept of genotype–phenotype correlations within HCH.
The findings help explain the considerable clinical variability observed in hypochondroplasia. Individuals with different FGFR3 variants may present with varying degrees of short stature, disproportion, radiographic abnormalities, and orthopaedic complications. This variability highlights the limitations of defining HCH solely by the presence or absence of the N540K mutation.
From a clinical perspective, these data support comprehensive FGFR3 sequencing in patients with a strong clinical and radiological diagnosis of HCH who test negative for common variants. The expanding catalogue of FGFR3 mutations continues to improve our understanding of skeletal growth regulation and the molecular basis of phenotypic diversity in FGFR3-related skeletal dysplasias.
Genetic counselling is recommended both before and after testing. It supports understanding of inheritance, recurrence risk, and the implications of test results, including uncertain findings.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.